From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type ?
Source Human
Target ACVR2B
CAS Number 1356922-05-8
ATC code none
ChemSpider none
Chemical data
Formula C6306H9732N1684O1990S46
Molar mass 142.4 kDa

Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013 it was announced that bimagrumab was granted breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by US Food and Drug Administration.[1]

Bimagrumab is currently entering Phase II development, with some research indicating clinical effects.[2] In 2016, Novartis intends to apply for FDA approval to treat sIBM patients with Bimagrumab BYM338.[3]